New drug combo shows promise for rare salivary gland cancer

NCT ID NCT04325828

First seen Nov 01, 2025 · Last updated May 11, 2026 · Updated 24 times

Summary

This phase 2 study tests whether a combination of two hormone-blocking drugs (apalutamide and a GnRH agonist) can shrink or slow advanced salivary gland cancers that have a specific protein called the androgen receptor. About 31 adults with locally advanced or spread salivary gland cancer will receive the treatment. The main goal is to see how many patients have their tumors shrink or disappear.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SALIVARY GLAND NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Aichi Cancer Center Hospital

    Nagoya, 464 8681, Japan

  • Hokkaido University Hospital

    Sapporo, 060-8648, Japan

  • Kansai Medical University Hospital

    Hirakata, 573 1191, Japan

  • National Cancer Center Hospital

    Chūōku, 104 0045, Japan

  • National Hospital Organization Kyushu Medical Center

    Fukuoka, 810 8563, Japan

  • National Hospital Organization Shikoku Cancer Center

    Matsuyama, 791 0280, Japan

  • Niigata University Medical And Dental Hospital

    Niigata, 951 8520, Japan

Conditions

Explore the condition pages connected to this study.